We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells
News

Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells

Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells
News

Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Various data, already presented at academic meetings, indicates that Medicyte’s upcyte® hepatocytes combine the benefits of quantity (generation of up to 2000 vials per donor) with the quality of primary hepatocytes. The new generation of upcyte® hepatocytes show more comparable results to primary cells in in-vitro assays (such as CYP 3A4-Induction, genotoxicity or hepato- and cytotoxicity). ‘With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market’ commented Dr. Joris Braspenning, CEO of Medicyte GmbH.

Advertisement